CytoSorbents Corporation (CTSO)

[andy55q]

Shares of biotech Vital Therapies Inc. slid more than 86% in premarket trade Wednesday, after the company said it is halting the development of a system aimed at treating liver failure after a disappointing trial. San Diego-based Vital said it does not believe its ELAD system, a cell-based therapy targeting the treatment of acute forms of liver failure, can win approval in the U.S. or European Union, without additional clinical trials that would cost money and require some time to complete. A trial of the therapy failed to meet its primary or secondary endpoints. "The company will cease any further development of the ELAD System and explore strategic options," Vital said in a statement. Shares have gained 5.5% in 2018 through Tuesday, while the S&P 500 has gained 8.0%.